What’s the Latest on ALS Research and Clinical Trials? www.massgeneralbrigham.org Nov. 21, 2026, 5:17 a.m.
Amyotrophic lateral sclerosis (ALS) research has reached a pivotal moment, marked by unprecedented funding, awareness, and therapeutic development, according to Dr. Sabrina Paganoni of Mass General Brigham's Neurological Clinical Research Institute. The progressive neurodegenerative disease attacks motor neurons controlling movement, swallowing, and breathing. While researchers have identified over 40 gene mutations associated with ALS, only approximately 10% of patients carry these mutations, highlighting the complexity of disease etiology. A major breakthrough came in 2023 when the FDA approved tofersen (Qalsody®), targeting superoxide dismutase 1 (SOD1) gene mutations found in 10%-20% of familial ALS cases and 1%-2% of sporadic cases. Dr. Paganoni describes this medication as "remarkable" for slowing disease progression and anticipates it will be the first of many mutation-targeted treatments. Current research efforts focus on understanding disease mechanisms, developing targeted therapies, and improving symptom management for patients and families. This convergence of scientific advancement and clinical innovation offers genuine hope for transformative ALS treatments.
Brain-Computer Interfaces and Neurotechnology for Spinal Cord Injury: What the SCI Community Should Know nascic.org Nov. 21, 2026, 5:17 a.m.
In 2010, Ian Burkhart sustained a complete C5 spinal cord injury while diving, resulting in quadriplegia with minimal arm movement and no hand function. Three years later, he was enrolled in the Reanimation in Tetraplegia clinical trial conducted by The Ohio State University Wexner Medical Center and Battelle Memorial Institute. In April 2014, Burkhart underwent brain surgery to receive a microelectrode array with 96 electrodes implanted in his motor cortex, paired with a flexible sleeve containing up to 130 electrodes around his forearm. This NeuroLife brain-computer interface (BCI) system used a trained decoding algorithm to translate his motor intentions into muscle stimulation. After seven months of data collection and algorithm training involving 300 hours of sessions, Burkhart successfully closed his hand around a spoon using only his intention in June 2014. This breakthrough demonstrated that neural bypass technology could restore voluntary hand and wrist control in paralyzed individuals, offering hope for therapeutic applications in spinal cord injury patients and validating further development of BCI systems for restoring motor function.
Noise resilience in brain decoding driven by spiking neural networks for responsive robot control www.frontiersin.org Nov. 21, 2026, 5:17 a.m.
Brain-computer interfaces (BCIs) hold significant promise across medical and commercial applications, yet their widespread adoption is hindered by data complexity and inevitable system noise. This study addresses this challenge by proposing a BCI pipeline utilizing spiking neural networks (SNNs) to enhance noise resilience in brain decoding through electroencephalography (EEG) classification. Researchers benchmarked a conventional shallow convolutional network against two SNN variants—one based on leaky integrate-and-fire (LIF) neurons and an adaptive LIF model—using the four-class BNCI 2014-001 motor imagery dataset. While the conventional CNN performed slightly better under clean conditions, it degraded significantly when exposed to corrupted input. The adaptive LIF SNN demonstrated remarkable robustness, with accuracy dropping only 0.80% under global Gaussian noise compared to the CNN's 58.56% drop. When trained on data with one electrode removed, the SNN retained 99.66% accuracy versus the CNN's 64% retention. The spiking models achieved this superior robustness while maintaining equivalent model size, requiring only 73% of the computational operations of the baseline. The team successfully integrated the SNN into a complete decoding-to-actuation pipeline controlling a Franka Emika Research 3 robot. These findings demonstrate that SNNs substantially reduce EEG decoding sensitivity to signal corruption, supporting their deployment in applications prioritizing robustness over peak accuracy.
Implantable Inductive Power Transfer: A Review of System Design, Safety, www.mdpi.com Nov. 21, 2026, 5:17 a.m.
# Professional Summary This comprehensive review examines implantable inductive power transfer (IPT) systems, a critical technology enabling wireless energy delivery to medical devices without percutaneous connections. The article provides an in-depth analysis of system design principles, safety considerations, and regulatory frameworks governing these devices. Inductive power transfer eliminates infection risks and mechanical failures associated with traditional wired connections, making it essential for next-generation implantable medical devices including pacemakers, neurostimulators, and drug delivery systems. The review synthesizes current technical approaches, coil design optimization, electromagnetic field safety standards, and biocompatibility requirements. By addressing both engineering specifications and clinical safety protocols, this work establishes foundational knowledge for developing reliable, efficient implantable IPT systems. The findings underscore the technology's importance in advancing patient outcomes through improved device longevity and reduced complications, positioning wireless power transfer as an emerging standard in implantable medical device innovation.
Brain-Computer Interface (#BCI) Voices www.linkedin.com Nov. 20, 2026, 2:09 p.m.
Brain-Computer Interface (#BCI) went from lab demos to real patients, real regulators and real capital this year. So I ranked the BCI voices you should be following, grouped by the companies leading on clinical progress, funding and commercial readiness. Here's the list.
Long-term safety and efficacy of intracortical microstimulation in humans www.science.org Nov. 19, 2026, 3:26 p.m.
Sensory feedback is essential for coordinated hand movement and limb control. Brain-computer interfaces targeting the somatosensory cortex could restore touch sensation in individuals with spinal cord injury, but the long-term safety and effectiveness remain unclear. Greenspon et al. found that intracortical microstimulation in the somatosensory cortex is safe, and the electrodes maintained sufficient activity for 2 to 10 years in five human patients with spinal cord injury. They observed no serious adverse events, and the electrodes consistently evoked sensations localized to the hand in participants. They found that about 60% of electrodes remained functional for up to 10 years despite gradual increases in stimulation thresholds. This study provides evidence that implantable neuromodulation devices may be safe and durable for many years in humans, supporting further development of brain-computer interface interventions for spinal cord injury. —Molly Ogle
The Long-Term Stability of Intracortical Microstimulation and the Foreign Body Response Are Layer Dependent www.frontiersin.org Nov. 19, 2026, 3:24 p.m.
Intracortical microstimulation (ICMS) of the somatosensory cortex (S1) can restore sensory function in patients with paralysis. Studies assessing the stability of ICMS have reported heterogeneous responses across electrodes and over time, potentially hindering the implementation and translatability of these technologies. The foreign body response (FBR) and the encapsulating glial scar have been associated with a decay in chronic performance of implanted electrodes. Moreover, the morphology, intrinsic properties, and function of cells vary across cortical layers, each potentially affecting the sensitivity to ICMS as well as the degree of the FBR across cortical depth. However, layer-by-layer comparisons of the long-term stability of ICMS as well as the extent of the astrocytic glial scar change across cortical layers have not been well explored. Here, we implanted silicon microelectrodes with electrode sites spanning all the layers of S1 in rats.
Brain-Computer Interfaces: The Next Compute-Medical Frontier Enters the Production Era the-investors-almanac.beehiiv.com Nov. 19, 2026, 3:19 p.m.
Neuralink has moved, in the span of 18 months, from a research program with a single patient into a company announcing high-volume production of a commercial medical device. Its valuation has followed the same trajectory. The last formal round, a Series E in May 2025, priced the company at $9.6 billion post-money. Every valuation signal since has come from secondary-market activity, which as of September 2026 implies a range between $29 billion and $42 billion, with individual bids reaching as high as $60 billion.
The BCI and Neurotech Sector Map 2026 the-investors-almanac.beehiiv.com Nov. 19, 2026, 3:18 p.m.
Who builds it, who funds it. An 11-page map of 28 companies across five segments, the strategic players around them, and 46 investors, with each company's stage, latest round, value and backers.
A small light source. A wider possibility. neurovlc.co.uk Nov. 18, 2026, 2:15 p.m.
NeuroVLC has unveiled an advanced neural recording system utilizing optical wireless communication technology to overcome limitations of traditional tethered recording methods. The system transmits 15.36 Mbps of uncompressed neural data through free-space optical links, eliminating susceptibility to radiofrequency interference and signal distortion from metal structures. The lightweight headmount weighs 2.5 grams or less, enabling untethered recording during natural animal behavior while reducing operational costs and timelines by 25 percent. The setup comprises a probe with Molex or Omnetics interface options that connects to a headstage containing an optical transmitter, sending data to overhead optical receivers that feed a stationary acquisition unit. This architecture provides real-time signal visualization and uncompressed data storage for detailed analysis. NeuroVLC indicates optical communication represents a pathway toward scaling neural recording to thousands of channels, as free-space optical systems have achieved 10 Gbps data rates in other industries. The company plans future research into powering neural interfaces without physical tethers and integrating optogenetic capabilities alongside recording, positioning this technology as a foundation for next-generation neuroscience applications.
Co-adaptive learning and domain adaptation bridge the translational gap in neuroprosthetic control: a review www.frontiersin.org Nov. 18, 2026, 2:14 p.m.
Myoelectric and neural prosthetic devices frequently fail in clinical practice despite laboratory success, a problem driven by domain shift—the non-stationary nature of biological signals caused by neural plasticity, motor learning, muscle fatigue, and electrode displacement. This comprehensive review by Ishika K. Kanakath synthesizes the neurophysiological and technical origins of domain shift and evaluates algorithmic strategies to address it. The analysis identifies that domain shift stems from coupled biological and technical processes, including cross-session drift and anatomical variability. Key countermeasures include closed-loop decoder adaptation, adaptive filtering, ensemble modeling, reinforcement learning, and transfer learning, each balancing adaptation speed against system stability. Critically, the review emphasizes co-adaptive systems where decoder updates interact with ongoing neural and motor plasticity. The research demonstrates that treating users as passive signal sources limits long-term control; instead, users must be viewed as active learning partners. Sustained improvements in neuroprosthetic reliability require integrating multiple adaptation strategies within a translational neuro-engineering framework that respects biological timescales. This integrated approach may reduce long-term prosthetic device abandonment and advance robust assistive neurotechnology for clinical populations worldwide.
XDAQ ONE+ - User Manual docs.kontex.io Nov. 18, 2026, 2:14 p.m.
KonteX Neuroscience has released the XDAQ ONE+, a versatile data acquisition platform designed for modern neuroscience research. This unified system supports up to 1024 channels of high-resolution spike recordings and includes XSR mode capabilities with 128 dynamically configurable channels for simultaneous recording or stimulation. The device natively supports advanced electrode technologies, including Neuropixels probes, with capacity for four probes operating simultaneously. Weighing 2.81 kilograms, the ONE+ integrates multiple experimental approaches into a single platform, addressing the need for flexible, multimodal acquisition solutions. Critical operational specifications include mandatory use of Thunderbolt 3 or higher cables—not USB-C substitutes—with support for certified cables up to three meters in length. Users must avoid connecting ports to unintended signal types to prevent permanent damage and should use KonteX-approved HDMI cables to avoid interference. The system supports firmware updates for bug fixes and new functionalities through KonteX's developer portal, with optional capability additions such as SR128 or Neuropixels support available post-purchase. This comprehensive solution enables researchers to conduct complex neurophysiological investigations with enhanced technical flexibility and performance.
Review Outlines Mechanical and Biological Failure Modes in Implanted Neural Interfaces bioengineer.org Nov. 18, 2026, 2:14 p.m.
Implanted neural interfaces—including cochlear implants, deep brain stimulation systems, and spinal cord stimulators—represent specialized bioelectronic devices designed to treat neurological conditions by interfacing directly with fragile neural tissue in the brain, spinal cord, and peripheral nerves. While these technologies have demonstrated remarkable clinical durability, often functioning for years or decades, a comprehensive review published in Bioelectronic Medicine examines the multifaceted failure modes threatening long-term reliability. Every critical component—from internal pulse generators and hermetic packaging to wireless power modules, flexible leads, and electrode surfaces—faces severe mechanical strain and biological challenges. The electronic core must generate controlled electrical pulses or digitize neural signals while operating in a hostile biological environment. Fully implantable systems eliminate transcutaneous wiring to prevent infection, but non-rechargeable batteries eventually deplete, necessitating invasive revision surgery. Understanding device longevity requires integrated knowledge of device physics, electrochemical limits, and cellular immune responses. As investigational trials expand to include high-density electrode arrays and endovascular recording systems, comprehending these mechanical and biological vulnerabilities becomes increasingly critical for optimizing clinical outcomes and extending device lifespan.
NORA: Neuro-headstage for Online Recording and Actuation in Freely Behaving Animal Models arxiv.org Nov. 18, 2026, 2:14 p.m.
Researchers have developed NORA, a compact wireless neuro-headstage that enables simultaneous neural recording and stimulation in freely behaving animal models. The device features separate recording and stimulation interfaces, each with dedicated microcontrollers and wireless modules, integrated into a head-mounted platform compatible with standard Omnetics connectors. This architectural separation prevents sample-dropping and stimulation waveform distortion during concurrent operations. To minimize stimulation artifacts and cross-domain interference, NORA employs electrical isolation between recording and stimulation subsystems, independent power domains, and separate wireless communication paths. In vivo animal experiments validated the platform, demonstrating neural feature acquisition comparable to commercial wireless headstages. The innovation addresses critical limitations in existing wireless neural interfaces, which often suffer from electrical coupling and timing conflicts when sharing power rails, communication modules, or processing resources. By maintaining design compatibility with established experimental workflows through standard connectors, NORA provides a practical, artifact-reduced platform advancing neuromodulation research and brain function studies in naturalistic behavioral conditions.
Revolutionizing brain‒computer interfaces: overcoming biocompatibility challenges in implantable neural interfaces link.springer.com Nov. 14, 2026, 11:36 a.m.
The primary limitation stems from the poor biocompatibility and mechanical mismatch between the interfacing electrodes and neural tissues, which induce a local immune response and scar tissue formation, thus decreasing the performance and useful lifespan. Therefore, neural interfaces should ideally exhibit appropriate stiffness and minimal foreign body reactions to mitigate neuroinflammation and enhance recording quality.
Brain-Computer Interface: Applications and Future of Neural AI www.burrus.com Nov. 14, 2026, 11:35 a.m.
A brain-computer interface is a direct communication pathway between the brain and an external device. Sometimes called a brain machine interface, it reads electrical brain signals from neurons and translates them into commands a computer or prosthetic can execute. No voice. No keyboard. Just thought. The technology has existed in experimental form since the 1970s. Recent advances in AI, miniaturized hardware, and neural signal processing systems have compressed the timeline dramatically. What once took decades in lab settings is now moving toward scalable commercial deployment.
Life Enhancement with Brain–Computer Interfaces | Sensors www.mdpi.com Nov. 14, 2026, 5:17 a.m.
Brain–computer interfaces (BCIs) are advancing rapidly as sensing technologies enabling neural signal acquisition, interpretation, and utilization across humans and animals. Originally designed for clinical neurorehabilitation, BCIs now support diverse applications including assistive communication, human–machine interaction, cognitive monitoring, and immersive environments. Recent progress in neural sensing modalities—electrophysiology, optical imaging, EEG, fNIRS, and implantable and wearable devices—combined with advances in low-power electronics and miniaturized sensors, has enabled increasingly detailed real-time recording of neural activity in naturalistic conditions. However, significant challenges persist, particularly regarding long-term signal stability, motion artifacts, device comfort in human applications, and achieving high spatial-temporal resolution while maintaining minimally invasive recording in animal studies. Current research increasingly emphasizes multimodal sensing strategies, adaptive signal processing, and closed-loop sensing-stimulation systems. A special issue on this topic seeks contributions addressing innovative sensor development and integrated hardware-software solutions demonstrating practical deployment in biomedical, behavioral, and intelligent interface applications, highlighting the need for interdisciplinary advances in sensor design, signal processing, and system integration.
X3R64-OM - User Manual docs.kontex.io Nov. 14, 2026, 5:17 a.m.
KonteX Neuroscience's X3R64-OM is a compact, high-performance 64-channel neural recording headstage weighing approximately 1.1 grams, designed for precise brain signal acquisition in research settings. The device leverages two RHD2132 amplifiers to deliver a single unified 64-channel data stream with low noise and high resolution. Measuring 14.58 × 11.3 × 6.7 millimeters, the headstage minimizes subject strain while maintaining fidelity. The system integrates seamlessly with the XDAQ acquisition platform and remains compatible with other established systems including Intan Recording Controllers, Open-Ephys acquisition boxes, and NeuroNexus Smartbox solutions. All X3R64 units include a default integrated 3-axis accelerometer sampling at the headstage input rate, providing motion tracking data through auxiliary channels. Users can select from three protective armor configurations—S, M, and IP variants—manufactured from chemically resistant polyoxymethylene with customization options available. The IP-rated armor with optional parylene coating meets IP68 standards, offering enhanced durability for diverse experimental environments. This technical advancement addresses the critical need for lightweight, reliable neural recording solutions in neuroscience research.
HC16 · 16-Channel Hybrid Package www.neuronexus.com Nov. 14, 2026, 5:16 a.m.
The HC16 is a 16-channel hybrid probe package featuring a thin-film polyimide ribbon cable measuring 21 millimeters in length, terminating in an Omnetics 16-pin connector. This innovative design mounts a silicon probe at one end of the flexible cable while attaching the opposite end to a printed circuit board with an integrated connector, creating mechanical decoupling between the probe and the head-fixed connector. The hybrid assembly combines silicon and polymer components, with the thin-film cable offering exceptional flexibility that permits slight twisting during use. Designed specifically for chronic implant applications, the HC16 allows the probe to move independently with brain tissue rather than remaining rigidly fixed, reducing mechanical stress and improving long-term biocompatibility. Weighing only 0.2 grams, the package interfaces with an Omnetics 32-pin connector on the headstage side and is available in multiple configurations. This solution addresses critical challenges in neuroscience research by providing reliable neural signal recording while minimizing tissue damage and implant-related complications during extended experimental periods.
NORA: Neuro-headstage for Online Recording and Actuation in Freely Behaving Animal Models arxiv.org Nov. 14, 2026, 5:16 a.m.
NORA is a compact wireless neuro-headstage that enables simultaneous neural recording and stimulation in freely behaving animals. The device features separate recording and stimulation interfaces, each with a dedicated microcontroller unit and wireless module, integrated into a fully head-mounted platform compatible with standard Omnetics connectors. This architectural separation prevents sample-dropping and stimulation waveform distortion during concurrent operations. To minimize stimulation artifacts and cross-domain interference, the system employs electrical isolation between recording and stimulation subsystems with independent power domains and dedicated wireless communication paths. In vivo validation demonstrated that NORA acquires meaningful neural features with performance comparable to commercial wireless headstages. The innovation addresses critical limitations in existing wireless neural interfaces, which often suffer from electrical coupling and timing conflicts when sharing resources. By offering artifact-reduced bidirectional neural recording and stimulation while maintaining compatibility with established experimental workflows, NORA provides a practical platform for advancing neuromodulation research and studying brain function under naturalistic conditions.